Bright Light Therapy During Residential Alcohol Withdrawal
Launched by CENTRE HOSPITALIER ST ANNE · Mar 11, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Bright Light Therapy During Residential Alcohol Withdrawal," is looking at how effective light therapy is for people going through alcohol withdrawal. Researchers want to see if this special light treatment can help patients feel better during their recovery from alcohol use disorder. The trial is currently recruiting participants, and it is open to both men and women aged 18 to 65 years who have been diagnosed with alcohol use disorder and have been in treatment for at least two weeks.
To join the study, participants need to have experienced heavy drinking in the month before starting treatment and should be motivated to stop drinking alcohol. They should also be able to understand the study and give their consent. However, people with certain eye conditions, those who have received light therapy in the past six months, pregnant or breastfeeding women, and those with severe mental health issues or other substance use disorders cannot participate. If someone joins, they can expect to receive either the light therapy or a placebo (a treatment that looks and feels like the real thing but has no therapeutic effect) and will be monitored throughout the trial to see how they respond.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be aged from 18 to 65 years old and have a diagnosis of Alcohol Use Disorder
- • Patients must be intreated for alcohol withdrawal, for at least two weeks
- • Patients must report heavy drinking episodes in the past month
- • Patients must be able to understand medical information and consent to the treatment
- • Patients must be considering a goal of abstinence from alcohol
- Exclusion Criteria:
- • Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitis pigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.)
- • Subjects who have already received light therapy in the last 6 months
- • Lactating of pregnant women
- • Psychiatric comorbidity requiring an intreatment, or risk of manic episode (subjects with depressive or anxious symptoms compatible with an out-treatment can be included)
- • Substance Use Disorder other than alcohol and/or tobacco
- • Severe cognitive impairment (MOCA \< 10)
- • Patients being under legal protection measure
About Centre Hospitalier St Anne
Centre Hospitalier St. Anne is a leading healthcare institution dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical research. With a strong emphasis on mental health and neurology, the center is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards and regulatory guidelines. By fostering collaboration among multidisciplinary teams of experienced researchers and healthcare professionals, Centre Hospitalier St. Anne aims to contribute to the development of new therapies and treatment modalities, ultimately enhancing the quality of care for patients in both local and global contexts.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, île De France, France
Paris, , France
Patients applied
Trial Officials
Pierre Alexis GEOFFROY, PhD
Principal Investigator
University Hospital Group for Psychiatry and Neurosciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported